Sam Slutsky
Stock Analyst at LifeSci Capital
(4.98)
# 64
Out of 4,707 analysts
651
Total ratings
55.4%
Success rate
49.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sam Slutsky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PYXS Pyxis Oncology | Maintained: Buy | $6 | $3.89 | +54.24% | 22 | Sep 9, 2026 | |
| ORKA Oruka Therapeutics | Maintained: Buy | $175 | $94.31 | +85.56% | 24 | Sep 9, 2026 | |
| SYRE Spyre Therapeutics | Maintained: Buy | $116 | $90.79 | +27.77% | 59 | Sep 8, 2026 | |
| ATTO Attovia Therapeutics | Maintained: Buy | $45 | $23.66 | +90.19% | 2 | Sep 5, 2026 | |
| TCRX TScan Therapeutics | Downgraded: Hold | n/a | $0.3448 | - | 23 | Sep 2, 2026 | |
| IMUX Immunic | Maintained: Buy | $56 | $12.74 | +339.56% | 6 | Sep 1, 2026 | |
| TSX: EPRX Eupraxia Pharmaceuticals Inc. | Maintained: Buy | $22.08 | $11.39 | +93.94% | 11 | Aug 27, 2026 | |
| QNCX Quince Therapeutics | Maintained: Buy | $99 → $98 | $29.50 | +232.20% | 3 | Aug 19, 2026 | |
| OBX Obsidian Therapeutics | Initiated Coverage: Buy | $43 | $18.73 | +129.58% | 1 | Aug 18, 2026 | |
| AVBP ArriVent BioPharma | Maintained: Buy | $42 → $43 | $30.28 | +42.01% | 27 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $45 | $29.17 | +54.27% | 8 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $24 | $10.99 | +118.48% | 44 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $55 | $35.28 | +55.90% | 51 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $60 → $70 | $59.37 | +17.90% | 38 | Aug 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $56 | $39.12 | +43.15% | 43 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $53 | $39.57 | +33.94% | 72 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $108 | $73.40 | +47.14% | 34 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 | $2.17 | +130.41% | 33 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $2.00 | - | 29 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $225 → $236 | $152.28 | +54.98% | 25 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $16 | $3.40 | +370.59% | 14 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $46 → $45 | $13.27 | +239.11% | 13 | Jul 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $170 | $118.95 | +42.92% | 35 | Jun 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $1.16 | $0.82 | n/a | 11 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $7.17 | n/a | 23 | Aug 9, 2023 |
Pyxis Oncology
Sep 9, 2026
Maintained: Buy
Price Target: $6
Current: $3.89
Upside: +54.24%
Oruka Therapeutics
Sep 9, 2026
Maintained: Buy
Price Target: $175
Current: $94.31
Upside: +85.56%
Spyre Therapeutics
Sep 8, 2026
Maintained: Buy
Price Target: $116
Current: $90.79
Upside: +27.77%
Attovia Therapeutics
Sep 5, 2026
Maintained: Buy
Price Target: $45
Current: $23.66
Upside: +90.19%
TScan Therapeutics
Sep 2, 2026
Downgraded: Hold
Price Target: n/a
Current: $0.3448
Upside: -
Immunic
Sep 1, 2026
Maintained: Buy
Price Target: $56
Current: $12.74
Upside: +339.56%
Eupraxia Pharmaceuticals Inc.
Aug 27, 2026
Maintained: Buy
Price Target: $22.08
Current: $11.39
Upside: +93.94%
Quince Therapeutics
Aug 19, 2026
Maintained: Buy
Price Target: $99 → $98
Current: $29.50
Upside: +232.20%
Obsidian Therapeutics
Aug 18, 2026
Initiated Coverage: Buy
Price Target: $43
Current: $18.73
Upside: +129.58%
ArriVent BioPharma
Aug 13, 2026
Maintained: Buy
Price Target: $42 → $43
Current: $30.28
Upside: +42.01%
Aug 11, 2026
Maintained: Buy
Price Target: $45
Current: $29.17
Upside: +54.27%
Aug 11, 2026
Maintained: Buy
Price Target: $24
Current: $10.99
Upside: +118.48%
Aug 10, 2026
Maintained: Buy
Price Target: $55
Current: $35.28
Upside: +55.90%
Aug 8, 2026
Rated: Buy
Price Target: $60 → $70
Current: $59.37
Upside: +17.90%
Aug 7, 2026
Maintained: Buy
Price Target: $56
Current: $39.12
Upside: +43.15%
Aug 7, 2026
Maintained: Buy
Price Target: $53
Current: $39.57
Upside: +33.94%
Aug 7, 2026
Maintained: Buy
Price Target: $108
Current: $73.40
Upside: +47.14%
Aug 6, 2026
Maintained: Buy
Price Target: $5
Current: $2.17
Upside: +130.41%
Aug 6, 2026
Maintained: Hold
Price Target: n/a
Current: $2.00
Upside: -
Aug 5, 2026
Maintained: Buy
Price Target: $225 → $236
Current: $152.28
Upside: +54.98%
Aug 5, 2026
Maintained: Buy
Price Target: $16
Current: $3.40
Upside: +370.59%
Jul 17, 2026
Rated: Buy
Price Target: $46 → $45
Current: $13.27
Upside: +239.11%
Jun 30, 2026
Maintained: Buy
Price Target: $170
Current: $118.95
Upside: +42.92%
Dec 14, 2023
Maintained: Hold
Price Target: $1.16
Current: $0.82
Upside: n/a
Aug 9, 2023
Rated: Hold
Price Target: n/a
Current: $7.17
Upside: n/a